In experimental MS it was shown that intracerebral administration of leptin significantly reduced the insulin doses required to control the blood glucose level, due to the weakening of insulin resistance and the decrease of production of glucagon, a functional antagonist of insulin [166,167]. Here, LEP is linked to myeloid sarcoma.